FCS Exec Outlines Oncology Leadership Strategies in JCO Article
Event summary
- FCS President Lucio N. Gordan coauthored a JCO article on leadership strategies for community oncology
- Article highlights operational challenges from scientific breakthroughs, precision medicine, and digital innovation
- FCS conducts over 180 active clinical trials annually through partnership with Sarah Cannon Research Institute
- U.S. sees more than 2 million new cancer cases yearly with survivorship projected to exceed 22 million by 2035
The big picture
Community oncology practices face increasing pressure to integrate advanced technologies while maintaining accessible, value-based care. FCS's leadership strategies reflect broader industry trends toward physician-administrator collaboration and digital transformation in cancer treatment delivery. The organization's clinical trial volume positions it as a key player in translating research innovations into practical patient care.
What we're watching
- Operational Scaling
- How FCS will balance technological integration with patient-centered care delivery
- Research Leadership
- Whether FCS can maintain its position as a clinical trial leader amid growing competition
- Policy Engagement
- The extent to which public policy will shape community oncology's operational framework
Related topics